Analysts Conflicted on These Healthcare Names: Amphastar Pharmaceuticals (NASDAQ: AMPH) and Agile Therapeutics (NASDAQ: AGRX)

By Jason Carr

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amphastar Pharmaceuticals (NASDAQ: AMPH) and Agile Therapeutics (NASDAQ: AGRX).

Amphastar Pharmaceuticals (NASDAQ: AMPH)

BMO Capital analyst Gary Nachman reiterated a Hold rating on Amphastar Pharmaceuticals (NASDAQ: AMPH) on July 26 and set a price target of $16. The company’s shares closed on Friday at $17.56.

According to TipRanks.com, Nachman is a 4-star analyst with an average return of 12.4% and a 60.3% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Sucampo Pharmaceuticals, Pacira Pharmaceuticals, and Zimmer Biomet Holdings.

Amphastar Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $18.50.

Agile Therapeutics (NASDAQ: AGRX)

Noble Financial analyst Kumaraguru Raja reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) on July 28. The company’s shares closed on Friday at $4.95.

According to TipRanks.com, Raja is a 1-star analyst with an average return of -11.1% and a 50.0% success rate. Raja covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Adamas Pharmaceuticals, and Corbus Pharmaceuticals.

Currently, the analyst consensus on Agile Therapeutics is Strong Buy and the average price target is $9, representing an 81.8% upside.

In a report issued on July 19, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $10 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.